News & Updates

‘Triple-G’ obesity drug also targets NAFLD in phase II trial
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023 byAudrey Abella

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
Palliative care for interstitial lung disease more difficult than for lung cancer
Palliative care for interstitial lung disease more difficult than for lung cancer
11 Jul 2023